GNS-214-C is under clinical development by GENUONE Sciences and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I drugs for Dyslipidemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GNS-214-C’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GNS-214-C overview

GNS-214-C is under development for the treatment of dyslipidemia. It is an incrementally modified drug (IMD). It is administered by oral route as a film coated tablet.

GENUONE Sciences overview

GENUONE Sciences, formerly Genu Pharma Co Ltd, a subsidiary of Genuone Science Co Ltd, is a CMO company that focuses on drug license registration and production manufacturing. The company is headquartered in Seoul City, Seoul, South Korea.

For a complete picture of GNS-214-C’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.